

Index

- 22q11 deletion syndrome (CATCH-22)
 - and autism spectrum disorders 462, 466
 - and mental retardation 370–1, 372
- acquired aphasia with epilepsy (Landau-Kleffner syndrome) 27–8, 40, 389–90, 400, 411–15
 - aetiology 413
 - assessment 400, 413
 - clinical management and treatment setting 413
 - clinical picture 400, 412–13
 - definition and classification 389–90, 411–12
 - differential diagnosis and co-morbidity 413
 - electrical status epilepticus of sleep (ESES) 413
 - epidemiology 412
 - ICD-10 and DSM-IV criteria 389–90, 411–12
 - information for patients and parents 414
 - main features and symptoms 412
 - pharmacotherapy 414
 - prognostic factors 415
 - short- and long-term outcome 414–15
 - sign language 413
 - speech–language treatment 413
 - treatment 413–14
 - treatment monitoring and evaluation 414
- ADHD (attention deficit hyperactivity disorder)
 - see also* hyperkinetic disorders
 - and autism spectrum disorders 460–1, 477
 - and DAMP 499
 - and infectious disorders of the brain 18–19
 - and substance use disorders 59–60, 62
 - and tic disorders 605, 606
 - and Tourette syndrome 605, 606
- adjustment disorders
 - aetiology 212–13
 - and acute stress reaction 216–17
 - and post-traumatic stress disorder (PTSD) 216–17
 - assessment 213–16
 - child's subjective evaluation of the stressor 214, 215
 - clinical picture 210, 212
 - cognitive behavioural interventions 217–18
 - coping strategies 213–15, 216
 - core components 210–11, 212
 - definition and classification 208
 - differential diagnosis 216–17
 - epidemiology 212
 - factors affecting the impact of experiences 212–13
 - historical development of the concept 207–8
 - ICD-10 and DSM-IV criteria 208, 209, 210, 211
 - identifying and linking the stressor 214
 - outcome 218–19
 - parental attitudes and psychopathology 214
 - prevalence rates 212
 - psychological support 217–18
 - psychopharmacological interventions 218
 - treatment 217–18
 - types of stressors 212–13
- affective disorders 110, 111 *see also* bipolar disorders; depressive disorders
 - and conduct disorders 531
 - ICD-10 and DSM-IV classifications 110, 111
- Angelman syndrome
 - and autism spectrum disorders 462, 466
 - and mental retardation 370–1, 372–3
- anorexia nervosa 273–4, 278, 280, 281, 285, 288, 289, 303 *see also* eating disorders
 - aetiology 281–4
 - age at onset 272
 - and autism spectrum disorders 464

- assessment 279–80, 281, 303
- biological risk factors 283
- clinical implications of epidemiology 275
- clinical management and treatment setting 284–5, 286
- clinical picture 275–81
- counselling 287
- definition and classification 273–4, 275
- development and maintenance of the disorders 283–4
- diagnostic instruments 277–8, 279
- dieting as major precipitating factor 275–7, 282, 283–4
- differential diagnosis and co-morbidity 277
- disturbance in body image 275–7
- DSM-IV criteria 273–4, 275
- epidemiology 275
- evaluation of treatment 281, 288
- family risk factors 282
- family therapy and counselling 286, 287
- genetic factors 283
- high risk groups 282–3
- iatrogenic factors 284
- ICD-10 criteria 273–5
- importance of nursing support 287
- individual risk factors 282
- inpatient treatment 284–5, 286
- main features and symptoms 275–7
- outcome 288–9
- pharmacotherapy 287–8
- physical complications due to 276–7
- precipitating events 283
- prevalence and incidence rates 275
- psycho-educational measures 287
- psychological interventions 286
- psychopathological symptoms 276
- purging and vomiting 275–7
- risk factors 281–4
- sex ratios and ethnicity 275
- sociocultural risk factors 282–3
- subtypes with bulimic features 273, 274–7
- supervision of diet 287
- treatment 281, 284–5, 288
- treatment in special units or centres 284–5, 286
- tube feeding or parenteral hyperalimentation 287
- vomiting and purging 275–7
- weight phobia (fear of becoming fat) 275–7
- antisocial behaviour *see* conduct disorders
- antisocial personality disorder *see* personality disorders
- anxiety disorders 144–5
 - aetiology 170–1
 - and autism spectrum disorders 464
 - and hyperkinetic disorders 497
 - and obsessive-compulsive disorders 193–4
 - association with substance use disorders 59–62
 - benefits of multidisciplinary approach 179
 - benzodiazepines 174
 - cognitive-behaviour therapy (CBT) 151–2, 171–2, 173
 - combined psychosocial and pharmacological treatments 176–7
 - combining treatments in a multidisciplinary approach 176–9
 - conditioning effects of life events 170–1
 - disease management model 176
 - generalized anxiety disorder (GAD) 150–2, 155, 158
 - genetic predisposition for anxiety 170–1
 - outcome 179–80
 - panic disorder (PD) 151–2, 158–9, 160, 162, 185–6
 - pharmacological interventions 173–6
 - psychosocial approach to treatment 176
 - psychosocial interventions 151–2, 171–2, 173
 - separation anxiety disorder (SAD) 145–7, 150, 151–2
 - serotonin reuptake inhibitors (SSRIs) 175–6
 - social phobia (social anxiety disorder) 151–2, 162–4, 165, 166
 - specific (isolated) phobias 151–2, 166–7, 168, 170
 - stages-of-treatment model 177–9
 - treatment 151–2, 171–2, 173, 178
 - tricyclic antidepressants 174–5
- aphasia *see* acquired aphasia with epilepsy
- Asperger syndrome 448–51, 452 *see also* autism spectrum disorders
 - and obsessive-compulsive disorders 193–4
- attachment
 - assessing quality of relationship with caregiver 576–8
 - attachment beyond infancy 581
 - attachment figures 575–6
 - child's strategy in attachment relationships 576
 - concept of 574–81
 - development of attachment behaviour in young children 575–6

- attachment (*cont.*)
 - disorganized attachment among maltreated children 578–9, 580
 - infant attachment categories 576–9
 - infant temperament and secure/insecure behaviour 581
 - parent–child interaction in disorganized dyads 580
 - parental behaviour in secure and insecure dyads 579–80
 - parental experience of trauma or loss 580
 - parental factors associated with disorganized attachment 580
 - parental mental illness or social disadvantage 580
 - patterns of attachment 574–5
 - predictive validity of infant attachment categories 578–9
 - research assessment of attachment in older children 581
 - research assessment of child attachment 576
 - secure, insecure and disorganized patterns 574–5
 - stability of attachment categories 580
 - Strange Situation Procedure 576–8
- attachment disorders 581–91
 - alternative nosology 583–5
 - and hyperkinetic disorders 498
 - assessment 591–3
 - child-focused interventions 594
 - clinical diagnosis 573–4
 - developmental research 573–4
 - disinhibited attachment disorder 589–91
 - effects of institutional care 573–4
 - history taking 591–2
 - ICD-10 and DSM-IV nosology 573–4, 581–2, 583
 - information from files 592
 - information from other agencies 593
 - interviews with parents and child 593
 - observation of child/caregiver interaction 592, 593
 - outcome for adopted children 596
 - outcome in non-clinical populations 595
 - outcome of family interventions 596
 - outcome of insecure or disorganized attachment 595
 - outcome of poor quality institutional care
 - parent–child interaction interventions 595
 - parent focused interventions 594
 - pharmacological treatments 595
 - providing a primary attachment figure in institutions 595
 - reactive attachment disorder 586–9
 - removal from parental care 595
 - treatment 593–5
 - treatment within the family 593–5
 - work of John Bowlby (1907–1990) 573–5
- autism spectrum disorders
 - 22q11 deletion syndrome 462, 466
 - acoustic hypersensitivity 462, 466
 - aetiology 472–4
 - and ADHD 460–1
 - and ADHD pharmacotherapy 477
 - and Angelman syndrome 462, 466
 - and anorexia nervosa 464
 - and anxiety disorders 464
 - and bipolar disorder 463–4, 478
 - and cerebral palsy 23–4
 - and conduct disorders 532
 - and DCD 460–1, 463
 - and depression 463
 - and eating disorders 464
 - and epilepsy 462, 465–6
 - and food rituals 464
 - and fragile X syndrome 462, 466
 - and hyperkinetic disorders 460–1, 495–6
 - and hypomelanosis of Ito 462
 - and mental retardation 466–7, 472
 - and Moebius syndrome 462, 466
 - and non-verbal learning disability 464–5
 - and personality disorders 464–5
 - and PKU 462, 466
 - and Rett syndrome 448, 462
 - and schizophreniform disorder 464–5
 - and selective mutism 464–5
 - and semantic pragmatic disorder 464–5
 - and Smith–Magenis syndrome 462
 - and tic disorders 463
 - and Tourette syndrome 463
 - and tuberous sclerosis 462, 466
 - applied behaviour analysis (ABA) 476–7
 - Asperger syndrome 448–51, 452
 - assessment 470–2
 - associated medical disorders 462, 465–7
 - atypical autism 448–52, 453
 - autism 448–52
 - behavioural repertoire restriction 458–9
 - bipolar disorder pharmacotherapy 478
 - brain dysfunctions 472–3

- brain imaging examinations 470, 471
- bullying and victimization 463
- catatonic features 464–5
- charlatans and miracle cures 479
- childhood disintegrative disorder 448–52
- clinical applicability of ICD-10/DSM-IV
 - definitions 452–4
- clinical management and treatment setting 474
- clinical medical–neurological examination 470, 471
- clinical picture 455–6, 461, 462, 472
- clinical presentation 460
- decreased pain cold/heat sensitivity 459–60
- definition and classification 448–50, 451, 452, 453, 454
- depression pharmacotherapy 477
- diagnostic clinical interview 468, 469
- diagnostic instruments 467–8, 470
- diagnostic instruments in the public domain 481–7
- diagnostic observation of child's behaviour 468, 469–70
- diagnostic rating scales 467–8, 469
- differential diagnosis and co-morbidity 460–1, 462, 467
- DSM-IV criteria 448, 450–4
- early course and clinical presentation 460
- education 475–6
- educational assessment 471–2
- EEG 470, 471
- environmental overstimulation 459–60, 464
- epidemiology 454–5
- epilepsy pharmacotherapy 477–8
- fixation on routines and rituals 458–9
- flexible imaginative skills lack 458–9
- genetic causal factors 472–3
- genetic/chromosomal analyses 470, 471
- hearing problems 462
- history of the concept 447
- hyperactivity 459–60
- hyperactivity in young children 466–7
- hypoactivity and resistance to change 459–60
- IDC-10 criteria 448–50, 451, 452–3, 454
- implications for clinical practice 455
- incidence rates 454–5
- information to parents and patients 479
- laboratory examinations 470, 471
- language acquisition 457–8
- language disorders 466–7
- main features and symptoms 455–6, 460
- memory abnormalities 459–60
- narrow interests and attention to detail 458–9
- neuropsychological dysfunction 473–4
- non-verbal communication impairment 458
- outcome 479–80
- oversensitivity to sensory stimuli 459–60
- partial tetrasomy/trisomy 15 syndrome 462, 466
- PDD (pervasive developmental disorders) 448
- PDD NOS (PDD not otherwise specified) 448, 450–2
- perceptual distortions/abnormalities 459–60
- pharmacotherapy 477–8
- prevalence rates 454
- problematic issues 479
- prognostic factors 480
- psychiatric co-morbidity screen 471
- psychoeducation 476–7
- psychological interventions 476–7
- psychological tests 468, 469–70
- psychosocial factors 473
- reciprocal communication impairment 457–8
- rubella embryopathy 462, 466
- sex chromosome aneuploidies 462, 466
- sex ratios 455
- short- and long-term outcome 479–80
- sleep disorder pharmacotherapy 478
- sleep disorders 459–60, 478
- social interaction impairment 457
- tic disorder pharmacotherapy 478
- terminology range 448
- treatment 474–9
- treatment algorithms and decision trees 475
- treatment for hyperactivity, violent outburst and self-injury 477
- treatment monitoring and evaluation 478
- binge eating disorder 272, 289–90, 291 *see also* bulimia nervosa
- bipolar disorders 129–30, 135
 - acute treatment of mania 134
 - aetiology 133
 - and autism spectrum disorders 463–4
 - and hyperkinetic disorders 497
 - assessment 132–3
 - carbamazine treatment and side effects 134–5
 - clinical applicability of adult criteria 131
 - clinical management and treatment setting 133–4
 - clinical picture 131–3
 - cyclothymia 130–1

bipolar disorders (*cont.*)

- definition and classification 130–1
 - delusions and hallucinations 131–2
 - diagnostic instruments 132
 - differential diagnosis 132
 - dysthymia 130–1
 - epidemiology 131
 - failure to respond to treatment 134–5
 - genetic factors 133
 - grandiose ideas due to mania 131–2
 - hyperthymia 130–1
 - ICD-10 and DSM-IV criteria 130–1
 - in preadolescents and adolescents 129–30
 - increased activity due to mania 131–2
 - indications for admission to hospital 133–4
 - lithium treatment and side effects 134–5
 - main features and symptoms of mania 131–2
 - mood elevation feature of mania 131–2
 - outcome 135
 - patient and family support 134
 - pharmacotherapy 134
 - poor compliance with treatment 134–5
 - prevalence and incidence rates 131
 - problematic issues 134–5
 - prophylactic treatment 134
 - psychological treatment 134
 - sex ratios 131
 - side effects of medications 134–5
 - sub-syndromal bipolar disorders 130–1
 - suicide risk 135
 - switching from depression to bipolar disorder 135
 - treatment 133–5
 - treatment of depression 134
- birth trauma, and hyperkinetic disorders 507–8
- borderline personality disorder
- aetiology 352–3
 - assessment process 349–51
 - clinical picture 346–8
 - co-morbidity 348–9
 - definition and classification 345–6
 - description 345
 - dialectical behaviour therapy (DBT) 353–61
 - differential diagnosis 348–9
 - DSM-IV criteria 345–6
 - ICD-10 diagnosis 345–6
 - patient's family involvement 361–2
 - pharmacotherapy 362
 - self-harm 347
 - standardized assessments 351

treatment 353–62

unstable and inappropriate relationships 346–8

- brain disorders 1–2 *see also* brain injury; brain tumours; cerebral palsy; epilepsy; infectious disorders of the brain; Minimal Brain Dysfunction (MBD)
- and hyperkinetic disorders 498
- and autism spectrum disorders 472–3
- brain injury 2–16
- aetiology 12
 - apallic syndrome 5–6
 - attention deficits and distractibility 6–7
 - behavioural interventions 13–14
 - causes and types of damage 12
 - clinical implications of epidemiology 3
 - clinical management and treatment setting 13
 - clinical picture 3–4, 10–11, 12
 - closed head injury 2, 12
 - definition and classification 2–3
 - diagnostic instruments and assessment 9–11, 12
 - differential diagnosis and co-morbidity 8–9
 - disturbance of executive functions 6–7
 - dysfunctional adaptation processes 8
 - educational consequences 4, 8
 - effects of pituitary damage 4, 6
 - endocrine effects 4, 6
 - epidemiology 3
 - family adaptation process 8
 - family counselling 13–14
 - Glasgow Coma Scale scoring 2–3
 - headaches 5–6
 - hormonal disturbances 4, 6
 - hydrocephalus 5–6
 - hypersomnolence 5–6
 - incidence and prevalence rates 3
 - individual adaptation process 8
 - intellectual impairment 6–7
 - language and communication skills impairment 6–7
 - learning and memory problems 6–7
 - main features and symptoms 3–4, 10–11, 12
 - mild, moderate and severe 2–3
 - movement disorder 5–6
 - multidisciplinary approach to treatment 13
 - neurocognitive impairment 4, 6–7
 - neurological symptoms 4, 5–6
 - neuropsychiatric features 3–4, 5
 - neuropsychiatric phases 3–4, 5
 - neuropsychological testing 10–11, 14
 - open head injury 2, 12

- outcome of mild, moderate and severe injuries 16
- problematic ethical issues 16
- psychological interventions 13–14
- psychopharmacotherapy 14, 15
- psychosocial consequences 8
- reduced speed of information processing 6–7
- seizures and epilepsy risk 5–6
- sex ratios 3
- sleep disturbances 5–6
- spasticity 5–6
- standardized checklists for evaluation 14
- supportive psychotherapy for the child 13–14
- treatment 13–16
- treatment monitoring and evaluation 14
- visual–perceptual motor skills deficits 6–7
- brain tumours 41–7
 - aetiology of psychiatric disorders 44–5
 - aetiology of brain tumours 44–5
 - assessment questionnaires and checklists 44, 46
 - chemotherapy 45–6
 - clinical implications of epidemiology 41–2
 - clinical management and treatment setting 45
 - clinical picture 42–4
 - cognitive impairments 43
 - counselling for the care team 45–6
 - cranial radiotherapy 45, 46
 - definition and classification 41
 - diagnostic instruments and assessment 44
 - differential diagnosis and co-morbidity 43–4
 - epidemiology 41–2
 - family counselling 45–6
 - hereditary effects 44–5
 - impact of medical therapy 43
 - incidence rates 41
 - location-related symptoms 42–3
 - main features and symptoms 42–3
 - malignancy rates 41–2
 - malignant tumours 46–7
 - neuroimaging to aid diagnosis 43–4
 - neuropsychological testing 46
 - neuropsychological testing 10–11, 44
 - outcome 47
 - patient and family counselling on process of dying 46–7
 - postradiation syndrome 46
 - psychiatric assistance to cope with treatment 45–6
 - psychiatric symptoms 42–3
 - psychological interventions 45–6
 - psychopharmacotherapy 15, 37–8, 46
 - psychosocial adaptation problems 43
 - surgical treatment 45
 - survival rates and long-term effects 47
 - treatment 45–7
 - treatment failure and fatality 46–7
 - treatment monitoring and evaluation 46
- bulimia nervosa 280, 281, 288, 289–90, 295, 298
 - see also* eating disorders
 - aetiology 294–6
 - age at onset 272
 - antidepressants 297
 - assessment 293–4
 - association with substance use
 - disorders/substance abuse 59–62, 293
 - atypical bulimia nervosa 289–90, 291
 - binge eating 289–90, 291
 - clinical implications of epidemiology 291–2
 - clinical management and treatment setting 296
 - clinical picture 280, 292–4
 - cognitive-behavioural interventions 296–7
 - definition and classification 289–90, 291
 - depression 292–3
 - diagnostic instruments 293
 - dieting risk factors 294–6
 - differential diagnosis and co-morbidity 293
 - DSM-IV and ICD-10 criteria 289–90, 291
 - epidemiology 291–2
 - genetic factors 294–6
 - hospitalization 296
 - in males 291, 292–3
 - individual and group therapy 296–7
 - job and career counselling 297
 - main features and symptoms 280, 292–3
 - medical complications 280, 292–3
 - multi-impulsive bulimia 293
 - nutritional counselling 297
 - outcome 298
 - pharmacotherapy 297
 - prevalence and incidence rates 291
 - psychiatric disorder risk factors 294–6
 - psycho-educational measures 297
 - psychological interventions 296–7
 - purging and vomiting 292–3
 - risk factors 294–6
 - self-harm 293, 294–6
 - sex ratio 291
 - shoplifting 293
 - social activity programmes 297

- bulimia nervosa (*cont.*)
 - subtypes 289–90, 291
 - suicidality 293
 - treatment 281, 288, 296–8
 - treatment monitoring and evaluation 281, 288, 297–8
 - vomiting and purging 292–3
- cerebral palsy 22–5
 - aetiology 24
 - aggressive behaviour 23–4
 - ataxia 22–3
 - autism 23–4
 - clinical implications of epidemiology 23
 - clinical picture 23–4
 - conduct disorders 23–4
 - defiant and negativistic behaviour 23–4
 - definition and classification 22
 - depressive disorders 23–5
 - determinants of psychiatric disorders 24
 - dyskinesia (athetosis) 22
 - emotional disorders 23–4
 - epidemiology 22–3
 - epilepsy 22, 23–5, 37–8
 - family approach to counselling and guidance 24–5
 - hyperkinetic disorders 23–5
 - IQ as predictor of psychiatric problems 23–4
 - learning difficulties 23–4
 - main features and symptoms 23–4
 - mental retardation 23–4
 - obsession and compulsion 24–5
 - outcome 25
 - phobias and anxieties 23–4
 - physiotherapy 24–5
 - prevalence of psychiatric disorders 23–4
 - prevalence rates 22–3
 - psychological interventions 24–5
 - psychopharmacological treatment 24–5
 - risk factors 24
 - seizures 22, 23–5, 37–8
 - social isolation 23–4
 - spastic diplegia 22–3, 24
 - spastic hemiplegia 22–3, 24
 - spastic quadriplegia or tetraplegia 22–3, 24
 - spasticity 22
 - special education 24–5
 - specific reading retardation 23–4
 - treatment 24–5, 37–8
 - treatment drug interactions 24–5
- child abuse *see* physical and sexual abuse
- chromosomal disorders, and hyperkinetic disorders 498
- chronic fatigue syndrome *see* somatoform disorders
- conduct disorders
 - adolescence-limited pattern 527
 - aetiology 536–42
 - and adjustment reaction to external stressor 531
 - and affective disorders 531
 - and antisocial personality disorder 532
 - and autistic spectrum disorders 532
 - and cerebral palsy 23–4
 - and depression 531
 - and dissocial/antisocial personality disorder 532
 - and hyperkinetic disorders 495, 531
 - and infectious disorders of the brain 18–19
 - and post-traumatic stress disorder 531
 - and socioeconomic status 528
 - and subcultural deviance 532
 - and voiding postponement 634
- assessment 532–6
- assessment formulation 536
- changes in rates over time 527
- classification 523–4, 525
- clinical applicability of ICD-10 and DSM-IV criteria 525
- clinical implications of epidemiology 528
- clinical management and treatment setting 542–3, 544
- clinical picture 528–36, 554–6
- cognitive assessment of the child 535
- cognitive behavioural therapy 547
- dealing with specific learning problems 548
- diagnostic instruments 532, 554–6
- differential diagnosis and co-morbidity 530–2
- early onset–lifetime persistent pattern 526–7
- epidemiology 526–8
- examination of child's mental state 534
- examination of child's physical state 534–5
- family functioning therapies 546–7
- fostering or adoption 542–3
- gender ratios 527
- ICD-10 and DSM-IV criteria 523–4, 525
- impact of enduring problems 530
- improving child's interpersonal skills 547
- improving classroom behaviour 548
- improving functioning at school 548
- influence of child's IQ 540–2

- influence of child's physiological characteristics 540–2
- influence of child's temperament and personality 540–2
- influence of child's thinking style 540–2
- influence of criminality of the father 539
- influence of environment beyond the family 539–40
- influence of family environment 537–9
- influence of genetic factors 536–7
- influence of neighbourhood and poverty 539–40
- influence of parent–child interaction patterns 537–8
- influence of parenting practices 538
- influence of peers 539–40
- influence of physical and sexual abuse 539
- influence of pre- and perinatal risk factors
- influence of psychiatric disorder in parents 538
- influence of school organization 539–40
- interviews with parents and siblings 533
- main features and symptoms 528–30
- onset patterns 526–7
- oppositional defiant disorder 523–4, 525
- outcome 551–3
- parent–child interaction observations 533–4
- parenting skills programmes 545–6
- patterns and consequences 522–3
- pharmacotherapy 548–9
- prevalence 526
- prevention 550–1
- prognostic factors 552–3
- rates in different countries and areas 528
- reducing deviant peer group influences 548
- reducing the impact of poverty 548
- school report 535–6, 554–6
- short- and long-term sequelae 551–2
- treatment 542–9
- treatment algorithms and decision trees 543–4
- treatment monitoring and evaluation 549
- typical behaviour by girls 529
- typical behaviour in adolescence (12 to 17 years) 529
- typical behaviour in middle childhood (8 to 11 years) 529
- typical behaviour in younger children (3 to 7 years) 528–9
- DAMP (Deficits in Attention, Motor Control and Perception) 47–9, 52
 - aetiology 51
 - and ADHD 499
 - autism spectrum disorders link 48–51
 - clinical implications of MBD/DAMP 48
 - clinical picture 48–51
 - emotional disorders 48–51
 - epidemiology of MBD/DAMP 48
 - family counselling 51–2
 - genetic link
 - main features and symptoms 48–51
 - oppositional and defiant behaviours 48–51
 - original concept of Minimal Brain Damage 47–8, 49
 - outcome 52
 - pre- and peri-natal problems
 - prevalence rates of MBD/DAMP 48
 - psychiatric disorders 48–51
 - psychological interventions 51–2
 - social isolation 48–51
 - treatment 51–2
 - use of DAMP descriptive label 48
- DCD (developmental coordination disorder)
 - and autism spectrum disorders 460–1, 463
 - and hyperkinetic disorders 499
- depressive disorders 110–12, 113, 117, 118, 122, 123, 126, 128, 129, 137–40, 141–3
 - aetiology 120–1
 - and autism spectrum disorders 463, 477
 - and conduct disorders 531
 - and hyperkinetic disorders 497
 - and obsessive-compulsive disorders 193–4
 - and substance use disorders 59–62
 - antidepressant treatment 125–7, 141–3
 - assessment 119–20
 - biological theories of causation 120–1
 - clinical applicability of adult criteria 113
 - clinical implications of epidemiology 114
 - clinical management and treatment setting 121–2, 123
 - clinical picture 114–18, 120, 137–40
 - cognitive changes 114–15
 - cognitive-behaviour therapy (CBT) 124–5
 - co-morbidity with other psychiatric disorders 111–13, 115–16
 - definition and classification 111–12, 113
 - differential diagnosis and co-morbidity 115–16
 - emotional symptoms 114–15
 - epidemiology 114
 - failure to respond to initial treatment 127–9
 - genetic factors 120–1
 - ICD-10 and DSM-IV criteria 111–12, 113

734 Index

- depressive disorders (*cont.*)
 - in children and adolescents 110–11
 - influence of chronic adversities 120–1
 - information for patients and parents 129, 141–3
 - interpersonal psychotherapy (IPT) 124–5
 - main features and symptoms 114–15, 137–40
 - major depressive conditions in pre-adolescent children 128–9
 - measurement of depression 117–18, 119, 137–40
 - motivational changes 114–15
 - neurovegetative symptoms 114–15
 - outcome 129
 - pharmacotherapy 125–7
 - precipitating stressful events 120–1
 - prevalence and incidence rates 114
 - problematic issues 127–9
 - prognostic factors 129
 - psychological interventions 124–5
 - psychological processes involved 120–1
 - psychotic and non-psychotic 111–13
 - range of services needed 125
 - sex ratios 114
 - short- and long-term outcome 129
 - suicide risk 114–15, 119–20, 121–2
 - treatment 112, 121–2, 123, 126, 128, 129, 137–40, 141–3
 - treatment algorithm 123–4
 - treatment monitoring and evaluation 112, 127, 137–40, 141–3
 - treatment non-compliance 127–9
 - treatment with fluoxetine and paroxetine 125–7, 141–3
 - treatment with SSRIs 125–7, 141–3
- dialectical behaviour therapy (DBT) 353–61
 - biosocial theory of borderline personality disorder 354–5
 - conflicts among professional staff 356–7
 - establishing a therapeutic team 360–1
 - opposing treatment strategies 355–7
 - principles 355–7
 - problem solving and validation 355–7
 - structuring progress through therapy 358–60
 - structuring the treatment programme 357–8
 - treatment in non-specialist settings 360–1
- diet, and hyperkinetic disorders 507–8
- disinhibited attachment disorder 589–91
 - aetiology 591
 - and institutional care 589–90
 - and multiple foster care 589
 - assessment 591–3
- child focused interventions 594
- clinical picture 590–1
- co-morbidity 591
- definition and classification 589
- differential diagnosis 590–1
- epidemiology 589–90
- history taking 591–2
- information from files 592
- information from other agencies 593
- interviews with parents and child 593
- main features and symptoms 589, 590
- observation of child/caregiver interaction 592, 593
- outcome for adopted children 596
- outcome in non-clinical populations 595
- outcome of family interventions 596
- outcome of insecure or disorganized attachment 595
- outcome of poor quality institutional care
- parent–child interaction interventions 595
- parent-focused interventions 594
- pharmacological treatments 595
- providing a primary attachment figure in institutions 595
- removal from parental care 595
- treatment 593–5
- treatment within the family 593–5
- dissocial (antisocial) personality disorder *see* personality disorders
- Down syndrome 370–2
- dyscalculia *see* mathematical difficulties and dyscalculia
- dyslexia *see* reading difficulties and dyslexia
- eating disorders 272 *see also* anorexia nervosa; bulimia nervosa
 - and autism spectrum disorders 464
 - and obsessive-compulsive disorders 193–4
- elective mutism (selective mutism)
 - aetiology 562–3
 - and autism spectrum disorders 464–5
 - assessment 560–2, 569–72
 - clinical management and treatment setting 564
 - clinical picture 560
 - cognitive behaviour therapy 565–6, 567
 - communication patterns
 - co-morbid disorders 559–60
 - definition and classification 557–8
 - differential diagnoses 559–60

- effects of bilingualism 562, 563
- effects of migration 563
- epidemiology 558
- ICD-10 and DSM-IV criteria 557–8
- information of patients and parents 568
- main features and symptoms 558–9
- maintaining factors 562–3
- onset of the disorder
- origin of designation 557
- outcome 569
- pharmacotherapy 567
- precipitating factors 562, 563
- predisposing factors 562–3
- problematic issues 568
- problems with ‘therapeutic pressure’ approach 568
- psychological interventions 564–6, 567
- treatment 564–7, 568
- treatment monitoring and evaluation 567–8
- elimination disorders 625 *see also* encopresis; enuresis
- emotional abuse *see* physical and sexual abuse
- encopresis 638–40, 642, 645, 646–50, 652–3
 - aetiology 642–3
 - clinical picture 639–40, 642, 646–50, 652–3
 - co-morbidity 641
 - consequences of acute constipation 642–3
 - definition and classification 638–9
 - diagnostic instruments 641–2, 646–50, 652–3
 - differential diagnosis 641
 - elimination disorders 625
 - enemas 644
 - epidemiology 639
 - genetic factors 642–3
 - Hirschsprung’s disease 641
 - ICD-10 and DSM-IV criteria 638–9
 - laxative treatment for constipation 644
 - main features and symptoms 640
 - outcome 645
 - prevalence 639
 - treatment 643–4
- enuresis 625–38
 - alarm treatment for nocturnal enuresis 635–6
 - and urinary incontinence 625–8
 - clinical implications of epidemiology 629
 - clinical picture 627, 628, 629–33, 646–50, 652–3
 - cognitive-behavioural therapy for daytime wetting 636–7
 - daytime wetting aetiology 633, 634
 - daytime wetting main features and symptoms 629, 630
 - daytime wetting subtypes 625–8
 - daytime wetting treatment 634–5, 636–7
 - definition and classification 625–8
 - detrusor–sphincter dyscoordination 630, 634
 - diagnostic instruments and assessment 631–3, 646–50, 652–3
 - differential diagnosis 630–1
 - elimination disorders 625
 - epidemiology 628–9
 - genetic factors 633–4
 - ICD-10 and DSM-IV criteria 625–8
 - nocturnal enuresis aetiology 633–4
 - nocturnal enuresis main features and symptoms 627, 628, 629–30, 650
 - nocturnal enuresis subtypes 625–8
 - nocturnal enuresis treatment 634–6
 - outcome 637–8
 - pharmacotherapy for daytime wetting 636–7
 - pharmacotherapy for nocturnal enuresis 635–6
 - prevalence 628
 - psychiatric co-morbidity 631
 - sex ratios 629
 - treatment 634
 - urge incontinence 630, 634
 - voiding postponement 630, 634
- epilepsy 25–41 *see also* acquired aphasia with epilepsy (Landau–Kleffner syndrome)
 - aetiology 31–3
 - and autism spectrum disorders 27–9, 36–9, 462, 465–6, 477–8
 - and bipolar disorder 37–8, 39
 - and cerebral palsy 22, 23–5, 37–8
 - and hyperkinetic disorders 27–9, 36–9, 498
 - and infectious disorders of the brain 22
 - antiepileptic drug (AED) treatment 34, 35–6
 - antiepileptic drug side effects 33
 - antiepileptic drug treatment and learning problems 29
 - assessment using standardized checklists 10–11
 - association between epilepsy and mental functioning 28–9
 - brain-related risk factors for psychopathology 32–3
 - brain surgery effects 33
 - causes of epilepsy 31–2
 - clinical implications of epidemiology 27
 - clinical management and treatment setting 33–4

epilepsy (*cont.*)

- clinical picture 10–11, 27–30, 31, 34
- CSWS (continuous spike-waves during slow-wave sleep) 27–8
- definition and classification 25–6
- depression, treatment 39
- developmental disorders, treatment 36–9
- diagnostic instruments and assessment 31
- differential diagnosis and co-morbidity 29–30, 31, 34
- EEG results 29–31
- epidemiology 26–7
- epileptic syndromes with psychiatric manifestations 27–8
- episodic dyscontrol syndromes, treatment 39
- ESES (Electric Status Epilepticus during Slow sleep) *see* CSWS
- family counselling 34
- generalized seizure 25–6
- hereditary aspects 31–3
- infantile spasms 27–8
- intermittent explosive disorders, treatment 39
- IQ level and epilepsy risk 28–9
- ketogenic diet
- language disorders 27–8
- learning problems creation 28–9
- Lennox–Gastaut syndrome 27–8
- main features and symptoms 27–9
- mental retardation 27–9
- migraine 29–30, 31
- mood instability, treatment 37–8, 39
- multidisciplinary team approach to care 33–4
- Munchausen's Syndrome (by proxy) 29–30, 31
- neuroimaging (including MRI)
- neuropsychiatric assessment 10–11
- nocturnal epilepsies 334
- nonepileptic paroxysmal (or periodic) events 29–30, 31
- outcome 40–1
- panic and anxiety disorders, treatment 39
- panic attacks 29–30, 31
- paradoxical or forced normalism 28
- partial seizure 25–6
- personality features 28–9
- pharmacotherapy 34, 35–8, 39
- prevalence of psychiatric disorders 26
- prevalence rates 26
- pseudo-seizures 29–30, 31
- psychological interventions for patient and family 34

psychopharmacotherapy for associated psychiatric disorders 36–9

psychoses and illogical thinking, treatment 39

psychosocial risk factors for psychopathology 33
rage attacks or episodic dyscontrol 27–8, 29–30, 31

regression in various functions 27–8

risk factors for psychopathology of epilepsy 32–3

schizophrenia-like psychosis risk 27–8

sleep disorders 29–30, 31

SSRIs 37–8, 39

surgical treatment 40

temporal lobe epilepsy (complex partial seizures) 27–8

tics and Tourette syndrome 29–30, 31

treatment 33–40

treatment drug interactions 36–8, 39

treatment monitoring and evaluation 39–40

treatment-related risk factors for psychopathology 33

vagal nerve stimulator implant

violent behaviour, treatment 39

Epstein–Barr virus 19–20

excessive daytime sleepiness (EDS) 322–30

adolescents 323

aetiology 328–9

assessment scheme 327–8

causes of intermittent EDS 325–6

causes of persistent EDS 325

chronotherapy 329

clinical implications of epidemiology 323

clinical picture 323–8

co-morbidity 326

conditions with increased sleep tendency 325–6

definition and classification 322

diagnostic instruments or procedures 326

differential diagnosis 326

disturbed overnight sleep as cause 324–5, 328–9

DSPS treatment 329

epidemiology 322–3

insufficient sleep as cause 323, 328–9

irregular sleep–wake schedule 323

Kleine–Levin syndrome 325–6, 328–9

main features and symptoms 323–6

motivated sleep phase delay 329

narcolepsy 325, 328–9

neurological disorders 325

obstructive sleep apnoea syndrome (OSAS)

324–5, 329

outcome 329–30

- periodic limb movements in sleep 324–5
- prevalence and incidence ratios 322–3
- sleep-related breathing difficulties 324–5, 329
- snoring 324–5
- treatment 329
- expressive language disorder 389–90, 392, 394–5, 398–9, 400, 402–7
 - aetiology 405
 - assessment 400, 405
 - behavioural treatments 406
 - clinical implications of epidemiology 403
 - clinical management and treatment setting 406
 - clinical picture 394–5, 398–9, 400, 404–5
 - definition and classification 389–90, 392, 402–3
 - diagnostic instruments 398–9, 405
 - differential diagnosis and co-morbidity 404–5
 - epidemiology 403
 - ICD-10 and DSM-IV-TR criteria 389–90, 392, 402–3
 - information for patients and parents 406
 - main features and symptoms 394–5, 404
 - outcome 407
 - pharmacotherapy 406
 - prevalence rates 403
 - prognostic factors 407
 - sex ratios 403
 - short- and long-term outcome 407
 - treatment 406
 - treatment monitoring and evaluation 406
- fetal alcohol effect, and mental retardation 370–1, 374
- fetal alcohol syndrome
 - and hyperkinetic disorders 498, 507–8
 - and mental retardation 370–1, 374
- fragile X syndrome
 - and autism spectrum disorders 462, 466
 - and hyperkinetic disorders 498
 - and mental retardation 370–1, 372
- gender identity disorder (GID)
 - aetiology 701–4
 - biological theories 703–4
 - childhood GID and transsexualism 699
 - child-related predisposing factors 703
 - clinical picture for adolescents 700–1
 - clinical picture for children 699–700
 - definitions and classification 696, 697, 698
 - epidemiology 697–9
 - gender dysphoria 697
 - gender identity development 695
 - genetic factors 704
 - ICD-10 and DSM-IV criteria 696, 697, 698
 - influence of pre-natal hormones 703–4
 - legal age limits for treatments 722
 - legal recognition of gender change 722
 - parent-related factors 702–3
 - prevalence of adolescent and adult transsexualism
 - prevalence of childhood GID 697–9
 - psychological and psychobiological theories 702
 - sex ratio 699
 - signs of developing GID in boys 700
 - signs of developing GID in girls 700
 - subtypes of GID and aetiological theories 701–2
 - transgenderism (use of term) 697
 - transsexualism (use of term) 697
- gender identity disorder (adolescents)
 - adolescent sex reassignment controversies 715–17
 - clinical management 713–21, 724, 725
 - clinical picture 700–1
 - development of transsexualism 715–17
 - diagnosis 713–15, 724, 725
 - diagnostic instruments 714–15, 724, 725
 - diagnostic procedure 714
 - differential diagnosis 715
 - dual-role transvestism 715
 - early hormone treatment 716–17
 - family therapy 717–18
 - hormone treatment 716–17, 718–21
 - irreversible interventions 721
 - legal age limits for treatments 722
 - legal recognition of gender change 722
 - persons who prefer to be sexless 715
 - phases in procedure towards sex reassignment 713–21
 - physical interventions and sex reassignment 718–21
 - psychological interventions 717–18
 - psychotherapy after sex reassignment 717
 - psychotherapy combined with pharmacotherapy 717
 - psychotherapy to help with sex reassignment decision 717–18
 - real life experience before sex reassignment 718
 - results of sex reassignment 721
 - reversible interventions 718–21
 - Scoptic syndrome 715, 717
 - sex reassignment 715–21

- gender identity disorder (adolescents) (*cont.*)
 - surgical interventions for sex reassignment 721
 - transient stress-related cross-dressing 715
 - transvestic fetishism 715
 - triadic therapy for sex reassignment 715–21
- gender identity disorder (children)
 - behaviour therapy 711
 - clinical management 704–13
 - clinical picture 699–700
 - combined therapy approaches 712
 - cross-dressing 712
 - diagnosis 704–8, 709, 710, 711
 - diagnostic instruments 707–8, 709, 710, 711, 723–4
 - diagnostic procedure 707
 - differential diagnosis
 - ethics of intervention 708–10
 - historic and current interventions 708–13
 - parent organizations 713
 - psychoanalytic therapies 711–12
 - treatment effectiveness 713
- generalized anxiety disorder (GAD) 150–2, 155, 158
 - aetiology of anxiety disorders 170–1
 - anxiety disorders among family members 157
 - assessment 151–2, 158
 - benzodiazepines 174
 - clinical implications of epidemiology 156
 - clinical picture 157–8
 - cognitive-behaviour therapy (CBT) 151–2, 171–2, 173
 - combined psychosocial and pharmacological treatments 176–7
 - combining treatments in a multidisciplinary approach 176–9
 - conditioning effects of life events 170–1
 - definition and classification 150–5, 156
 - differential diagnosis and co-morbidity 157–8
 - disease management model for anxiety disorders 176
 - DSM-IV and ICD-10 classification 150–5, 156
 - epidemiology 156
 - genetic predisposition for anxiety 170–1
 - main features and symptoms 157
 - multidisciplinary approach 176–9
 - outcome for anxiety disorders 179–80
 - perfectionist children 157
 - pharmacological interventions 173–6
 - prevalence and incidence rates 156
 - psychosocial approach to treatment 176
 - psychosocial interventions 151–2, 171–2, 173
 - serotonin reuptake inhibitors (SSRIs) 175–6
 - sex ratios and ethnicity 156
 - stages-of-treatment model 177–9
 - treatment of anxiety disorders 151–2, 171–2, 173, 178
 - tricyclic antidepressants 174–5
- head injury, open and closed types 2, 12 *see also* brain injury
- hearing disability
 - and autism spectrum disorders 462, 466
 - and hyperkinetic disorders 498
- Hirschsprung's disease 641
- HIV infection
 - effects on the brain 18–20
 - risk with substance use disorders 58–9
- hyperactivity *see* hyperkinetic disorders
- hyperkinetic disorders
 - ADHD (attention deficit hyperactivity disorder)
 - criteria 490
 - adverse effects of medication 515–16
 - aetiology 506–9
 - and anatomical changes in the brain 508–9
 - and anxiety and depression 497
 - and attachment disorders 498
 - and autism spectrum disorders 460–1, 495–6
 - and bipolar disorder 497
 - and birth trauma 507–8
 - and brain disorders 498
 - and cerebral palsy 23–5
 - and chromosomal disorders 498
 - and cognitive impairments 508–9
 - and conduct disorders 495, 531
 - and DAMP 499
 - and DCD 499
 - and epilepsy 498
 - and fetal alcohol syndrome 498, 507–8
 - and fragile X syndrome 498
 - and hearing disability 498
 - and lead exposure 498, 507–8
 - and learning disability 499
 - and low IQ 499
 - and medical disorders 498
 - and motor disability 499
 - and oppositional disorders 495
 - and Sanfillipo syndrome 498
 - and specific learning difficulties 499
 - and tic disorders 498, 605, 606

- and Tourette disorder 498
- and tuberous sclerosis 498
- and Williams syndrome 498
- assessment 505–6
- attitude of parents towards treatment 509–10
- attitude of schools 509–10
- attitude of the child towards treatment 509–10
- behaviour therapy 509–12, 513–14, 519
- behavioural observation for diagnosis 500–1, 503
- clinical applicability of DSM-IV/ICD-10 criteria 490–2
- clinical implications of epidemiology 492
- clinical management 509–10
- clinical picture 493–5, 501, 502–3, 504, 506
- definition and classification 489–92
- diagnostic clinical interview 500, 502–3
- diagnostic instruments 499–501, 502–3
- dietary influences 507–8
- differential diagnosis and co-morbidity 494–5, 499
- distractibility 493–4
- DSM-IV criteria 490
- duration of drug treatment 517–18
- early psychological influences 507–8
- environmental influences 506–9
- epidemiology 492
- forgetfulness 493–4
- genetic influences 506–7
- hyperactivity in children 489
- hyperkinetic disorder sub-group of ADHD 490–2
- ICD-10 criteria 489–90
- impulsiveness 493–4
- inattentiveness 493–4
- lack of attention to detail 493–4
- lack of response to stimulant medication 516–17
- main features and symptoms 493–4
- other forms of disruptive behaviour 495
- outcome 518
- overactivity 493
- pharmacotherapy 504–5, 509–12, 514–18
- prevalence rates 492
- psychological interventions 509–12, 513–14, 519
- psychological tests 503, 504
- rating scales 499–500, 501
- sex ratios 492
- treatment 509–18
- treatment algorithms 510–12
- treatment monitoring and evaluation 515–16
- treatment with stimulants 504–5, 509–12, 514–18
- use of clinical checklists 501–3
- hypomelanosis of Ito
 - and autism spectrum disorders 462
 - and mental retardation 370–1
- infectious disorders of the brain 16–22
 - acute symptoms and chronic sequelae 17–18, 19
 - aetiology 19–20
 - and ADHD 18–19
 - and autism and autistic like conditions 17, 18–20
 - and epilepsy 22
 - and mental retardation 17
 - and OCD 17, 18–20
 - and schizophreniform psychosis 18–19
 - and tic disorders 17, 18–20, 22
 - and Tourette syndrome 18–20
 - arboviruses 19–20
 - bacterial meningitis 16, 17–18, 19–20, 21, 22
 - Borrelia burgdorferi* infection and Lyme disease 18–19
 - chronic fatigue syndrome 18–19
 - clinical implications of epidemiology 17
 - clinical management and treatment setting 20
 - clinical picture 17–18, 19
 - conduct disorders 18–19
 - congenital infections 18–19, 22
 - cytomegalovirus (CMV) 16, 18–20
 - definition and classification 16
 - differential diagnosis and assessment 19
 - encephalitis, viral 16, 17–18, 19–20, 21, 22
 - encephalopathy 18–19
 - enteroviruses 19–20
 - epidemiology 17
 - Epstein–Barr virus 19–20
 - herpes 17
 - herpes encephalitis 18–20, 22
 - herpes simplex type 1 virus 19–20
 - HIV infection 18–20
 - infections associated with psychiatric disorders 18–19
 - infectious agents 16, 17, 19–20
 - long-term psychosocial adaptation 20
 - Lyme disease 18–19
 - main features and symptoms 17–18, 19
 - meningitis, bacterial 16, 17–18, 19–20, 21, 22
 - meningitis, viral 16, 17–18, 19–20, 21–2
 - mononucleosis 18–19

- infectious disorders of the brain (*cont.*)
 mycoplasma encephalitis 18–19, 22
 neuropsychological testing 10–11, 21
 outcome 22
 patient and family guidance and information 21–2
 patient and family re-adjustment 21
 pharmacotherapy 21
 prevalence and incidence rates 17
 psychological interventions 21
 rabies 19–20
 rehabilitation through psychological interventions 21
 rubella 17, 18–19
 sex ratio 17
 streptococcal infections 17, 18–19, 22
 treatment 10–11, 20–2, 37–8
 treatment drug interactions 21, 37–8
 treatment monitoring and evaluation 21
 use of standardized checklists for evaluation 21
 viral encephalitis 16, 17–18, 19–20, 21, 22
 viral meningitis 16, 17–18, 19–20, 21–2
 IQ, low IQ and hyperkinetic disorders 499
- Kleine–Levin syndrome 325–6, 328–9
- Landau–Kleffner syndrome *see* acquired aphasia with epilepsy
- language disorders *see* speech and language disorders
- lead exposure, and hyperkinetic disorders 498, 507–8
- learning disability *see* mental retardation
- learning disorders *see also* mathematical difficulties and dyscalculia; reading difficulties and dyslexia
 aetiology 435–8
 and tic disorders 607
 assessment 434–5
 clinical picture 426–8, 432, 433, 435
 co-morbidity 434
 definition and classification 417–20, 421, 422, 424
 diagnostic instruments in the public domain 446
 differential diagnosis 433
 DSM-IV and ICD-10 criteria 417–20, 421, 422, 424
 epidemiology 424–6
 information for parents and children (websites) 446
 outcome 441–5
 range of specific learning difficulties 417
 treatment 438–41
 Lennox–Gastaut syndrome 27–8
 literacy disorders *see* reading difficulties and dyslexia
- mania *see* bipolar disorders
- mathematical difficulties and dyscalculia
 aetiology 438
 assessment 434–5
 clinical implications of epidemiology 426
 clinical picture 431–5
 co-morbidity 434
 definition and classification 417–20, 421, 422, 424
 diagnostic instruments in the public domain 446
 differential diagnosis 433
 DSM-IV and ICD-10 criteria 417–20, 421, 422, 424
 educational management and treatment setting 439
 epidemiology 425–6
 information for parents and children (websites) 446
 numeracy development 431–2
 outcomes 445
 prevalence 425–6
 range of specific learning difficulties 417
 sex ratios 426
 treatment 438
 treatment monitoring and evaluation 441
 types of learning difficulties 432–3
- medical disorders
 and hyperkinetic disorders 498
 associated with autism spectrum disorders 462, 465–7
- mental retardation
 22q11 deletion syndrome (CATCH-22) 370–1, 372
 aetiology 379–81
 and autism spectrum disorders 372–3, 466–7, 472
 and hyperkinetic disorders 499
 Angelman syndrome 370–1, 372–3
 assessment 375–7, 379
 behavioural and emotional problems 370
 attitudes to people with mental retardation 384
 behavioural phenotype syndromes (genetic syndromes) 370–4

- cerebral palsy 370–1
- clinical implications of epidemiology 368
- clinical management and treatment setting 381
- clinical picture 368–9, 379
- coaching and direct 'hands on' support 383–4
- decision tree for diagnosis 374–5
- definition and classification 364–7
- diagnostic instruments 375
- diagnostic instruments in the public domain 386
- differential diagnosis and co-morbidity 369
- Down syndrome 370–2
- DSM-IV criteria
- effects on the family 385
- environmental causes 380–1
- epidemiology 367–8
- epilepsy 370–1
- fetal alcohol effect (FAE) 370–1, 374
- fetal alcohol syndrome (FAS) 370–1, 374
- follow-up into adult stage 384
- fragile-X syndrome 370–1, 372
- genetic causes 379–80
- genetic syndromes (behavioural phenotype syndromes) 370–4
- hypomelanosis of Ito 370–1
- ICD-10 criteria
- incidence rates 367
- information to parents and patients 383
- IQ testing 364–7
- laboratory investigations 378
- language delay and language disorder 370
- links with medical conditions 364
- main features and symptoms 368–9
- medical disorders 370–1
- mortality 385
- neurofibromatosis 370–1
- neuromuscular disorders 370–1
- outcome 384–6
- pharmacotherapy 382–3
- Prader–Willi syndrome 370–1, 372–3
- prevalence rates 367
- problematic issues 384
- prognostic factors 385–6
- psychiatric disorders 370
- psychological interventions 382
- psychosocial environmental causes 380–1
- quality of life 385
- range of learning disabilities 364
- Rett syndrome 370–1, 373–4
- sex chromosome aneuploidies 370–1
- sex ratios 368
- short- and long-term outcome 384–5
- Smith–Magenis syndrome 370–1, 373
- treatment 381–4
- treatment algorithms and decision trees 381–2
- treatment monitoring and evaluation 383
- tuberous sclerosis 370–1
- visual and hearing impairments 374
- Minimal Brain Dysfunction (MBD) (syndromes attributed to) 47–9, 52
- ADD (attention deficit disorder) 47–8, 49
- ADHD (attention deficit hyperactivity disorder) 47–8, 49
- aetiology of DAMP 51
- autism spectrum disorders link with DAMP 48–51
- clinical picture for DAMP 48–51
- DAMP (deficits in attention, motor control and perception) 47–9, 52
- DCD (developmental coordination disorder) 47–8, 49
- emotional disorders associated with DAMP 48–51
- epidemiology of MBD/DAMP 48
- family counselling 51–2
- hyperkinetic disorder 47–8, 49
- implications of MBD/DAMP for clinical practice 48
- main features and symptoms of DAMP 48–51
- oppositional and defiant behaviours associated with DAMP 48–51
- original concept of Minimal Brain Damage 47–8, 49
- outcome 52
- prevalence rates of MBD/DAMP 48
- psychiatric disorders associated with DAMP 48–51
- psychological interventions 51–2
- social isolation associated with DAMP 48–51
- treatment of DAMP 51–2
- use of DAMP descriptive label 48
- Moebius syndrome, and autism spectrum disorders 462, 466
- mood disorders 110, 111 *see also* bipolar disorder; depressive disorders
- motor disability, and hyperkinetic disorders 499

- Munchausen Syndrome (by proxy) 29–30, 31, 672–3, 674–5
- mutism *see* elective mutism
- neglect *see* physical and sexual abuse
- neurasthenia (chronic fatigue syndrome) *see* somatoform disorders
- non-verbal learning disability 417
and autism spectrum disorders 464–5
- number skills disorders *see* mathematical difficulties and dyscalculia
- OCD (obsessive-compulsive disorders) 188
aetiology 195–6
and anxiety disorders 193–4
and Asperger syndrome 193–4
and cerebral palsy 24–5
and depressive symptoms 193–4
and eating disorders 193–4
and infectious disorders of the brain 17, 18–20
and schizophrenia 193–4
and tic disorders 605–6
and Tourette syndrome 193–4, 605–6
assessment 194–5
clinical implications of epidemiology 192
clinical picture 192, 193
cognitive behavioural therapy (CBT) 197–200, 201
common symptoms 192, 193
compulsions 188–9
definition and classification 188–9, 190
diagnostic instruments 194–5
differential diagnosis and co-morbidity 193–4
discontinuation of medication 203
DSM-IV and ICD-10 criteria 188–9, 190
duration of medication treatment 202–3
effective medication doses 202
epidemiology 189–92
incidence rates 189–92
information for patient and family 196–7
obsessions 188–9
outcome 204
PANDAS subtype of OCD 195–6
poor or non-responders to treatment 203
prevalence rates 189, 191
psychopharmacological treatment 201–3
treatment 196–203
treatment algorithms 196–7, 198
treatment augmentation strategies 203
treatment compliance 203
treatment general principles 196
treatment of obsessions and mental rituals 200–1
use of SSRIs 201–3
oppositional defiant behaviour *see* conduct disorders
overanxious disorder *see* generalized anxiety disorder
- panic disorder (PD) 151–2, 158–9, 160, 162, 185–6
aetiology of anxiety disorders 170–1
agoraphobia 151–2, 158–9, 160, 161–2, 185–6
assessment 151–2, 162, 185–6
benefits of multidisciplinary approach 179
benzodiazepines 174
clinical implications of epidemiology 161
clinical picture 151–2, 161–2, 185–6
cognitive-behaviour therapy (CBT) 151–2, 171–2, 173
combined psychosocial and pharmacological treatments 176–7
combining treatments in a multidisciplinary approach 176–9
conditioning effects of life events 170–1
definition and classification 158–9, 160, 161
differential diagnosis and co-morbidity 162
disease management model for anxiety disorders 176
DSM-IV and ICD-10 criteria 158–9, 160, 161
epidemiology 161
genetic predisposition for anxiety 170–1
main features and symptoms 161
multidisciplinary approach 176–9
outcome for anxiety disorders 179–80
pharmacological interventions 173–6
prevalence and incidence rates 161
psychosocial approach to treatment 176
psychosocial interventions 151–2, 171–2, 173
serotonin reuptake inhibitors (SSRIs) 175–6
sex ratios and ethnicity 161
stages-of-treatment model 177–9
treatment of anxiety disorders 151–2, 171–2, 173, 178
tricyclic antidepressants 174–5
- parasomnias 330–7
aetiology 336
assessment 335–6
clinical implications of epidemiology 331
clinical picture 331–6
confusional arousal 332–3

- deep NREM sleep parasomnias 332–3
- definition and classification 330
- differential diagnosis and co-morbidity 335
- disorders of arousal 332–3
- epidemiology 330–1
- light NREM sleep parasomnias 332
- main features and symptoms 331–3
- nightmares 333
- nocturnal enuresis 333
- nocturnal epilepsies 334
- outcome 337
- parasomnia overlap disorder 333
- parasomnias of physical origin 334
- prevalence and incidence 330–1
- primary parasomnias 330
- REM sleep behaviour disorder 333
- REM sleep parasomnias 333
- secondary parasomnias 330, 333
- secondary to psychiatric disorders 334
- sleep onset parasomnias 331–2
- sleep terrors (night terrors) 332–3
- sleepwalking 333
- sleepwalking 332–3
- treatment 336–7
- waking parasomnias 333
- partial tetrasomy/trisomy 15 syndrome, and
 - autism spectrum disorders 462, 466
- PDD (pervasive developmental disorders) *see also*
 - autism spectrum disorders
 - and reactive attachment disorder 587
- personality disorders *see also* borderline
 - personality disorder
 - and autism spectrum disorders 464–5
 - antisocial (dissocial) personality disorder 345
 - concepts of 339–40
 - controversial issues concerning definition 341–3
 - DSM-IV and ICD-10 criteria 340, 341
 - issues concerning diagnosis in adolescence 343–5
 - Schizotypal personality disorder 344–5
 - standard definitions 340, 341
- physical and sexual abuse
 - aetiology 679–81
 - assessment 677–9
 - association with poverty and lack of social resources 680–1
 - characteristics of abusers 680–1
 - characteristics of abusive and neglectful parents 680–1
 - clinical implications of epidemiology 662
 - clinical management 681–5
 - clinical picture 662–79
 - contexts in which sexual abuse occurs 663, 665
 - definition and classification 656–9
 - definition of emotional abuse 657
 - definition of neglect 657
 - definition of physical abuse 657
 - definition of sexual abuse 657
 - deliberate suffocation
 - diagnosis of Factitious Illness by Proxy 674–5
 - diagnosis of Munchausen Syndrome by Proxy 674–5
 - diagnosis of physical abuse 674
 - diagnosis of sexual abuse 675–6
 - diagnostic instruments 676–7, 693–4
 - differential diagnoses 674–6
 - disclosure of abuse 685
 - effects of parental marital breakdown 671–2
 - effects of parental psychiatric illness 671–2
 - effects on adaptation to school 669–70
 - effects on development of attachments 665–7, 685–6
 - effects on long term mental and physical health 670
 - effects on peer relationships 669
 - effects on regulation of emotions 665–8, 685–6
 - effects on sense of self 665–7, 668–9, 685–6
 - epidemiology 659–62
 - evidence for effectiveness of intervention 687–8
 - family assessments 678–9
 - general impact of abuse on development 665–9
 - growing awareness of the problem 655–6
 - harmful effects of child abuse 657, 658
 - harmful effects of emotional abuse 671–2
 - harmful effects of illness induction 672–3
 - harmful effects of physical abuse 670–1
 - harmful effects of physical neglect 672
 - harmful effects of sexual abuse 673–4
 - ICD-10 and DSM-IV criteria 657–9
 - immediate safety and health needs of the child 681–5
 - in-depth interviews with the child 677–8
 - incestuous abuse 671–2
 - levels of professional recognition or public awareness 660
 - longer term effects of abuse 689–90
 - Munchausen Syndrome by Proxy 672–3, 674–5
 - official reporting rates 660
 - outcome 688–91
 - paedophiles 679–81

- physical and sexual abuse (*cont.*)
 - parental emotional abuse 671–2
 - parents' attitudes to the abuse 678–9, 681
 - presentation of physical abuse 662–3, 664
 - presentation of sexual abuse 664, 666
 - prevalence and incidence rates 659–62
 - prognostic factors 690–1
 - protective factors in sexual abuse 681
 - rehabilitation phase of treatment 686–7
 - responsibility for identifying the presence of abuse 681–5
 - short-term effects of abuse 688–9
 - specific effects of abuse on development 669–74
 - therapeutic work 685–7
 - treatment 681–8
 - treatment when the child is safe 685–6
 - vulnerability factors for children 679–81
 - when the child needs a new family 687
 - WHO definition of child abuse 656
- phobias *see* social phobia; specific (isolated) phobias
- PKU, and autism spectrum disorders 462, 466
- post-traumatic stress disorder (PTSD)
 - acute stress reactions 229–31
 - aetiology 236–7
 - and conduct disorders 531
 - association with substance use disorders 59–62
 - child-related risk and protective factors 237
 - clinical applicability of adult criteria 225–7, 228
 - clinical implications of epidemiology 229
 - clinical management and setting 238
 - clinical picture 229–33, 236
 - cognitive-behaviour therapy (CBT) 239–41
 - crisis or impact phase interventions 238
 - definition and classification 221–2, 224–5, 227, 228
 - developmentally appropriate diagnostic criteria 225–7, 228
 - diagnosis and nature and timing of trauma 231
 - diagnostic instruments 232–3, 234
 - differential diagnosis and co-morbidity 231
 - DSM-IV diagnostic criteria 223–5
 - epidemiology 228–9
 - exposure and habituation 243
 - eye movement desensitization (EMDR) 241–2
 - family-related risk and protective factors 237
 - group or individual therapy 243
 - ICD-10 diagnostic criteria 222–3
 - immediate post-trauma interventions 238
 - interview with the child 234–6
 - interview with the parents/carers 234, 236
 - main features and symptoms 229–31
 - outcome 244
 - parents'/carers' role in interventions 242
 - pharmacotherapy 242–3
 - prevalence and incidence rates 228
 - problematic issues 243
 - psychological debriefing 238
 - psychological interventions 238–42
 - recognition that children can be affected 221
 - risk and protective factors 236–7
 - sex ratios 228–9
 - sleep problems and nightmares 229–30
 - survivor guilt and self-blame 229–30
 - trauma avoidance 230–1
 - trauma re-experiencing and flashbacks 229–31
 - trauma-related risk factors for PTSD 237
 - treatment 238–43
 - treatment monitoring and evaluation 243
 - treatment on basis of clinical need 226–8
- Prader–Willi syndrome, and mental retardation 370–1, 372–3
- rabies 19–20
- reactive attachment disorder
 - aetiology 588–9
 - and neglect and abuse 586–7
 - and PDD (pervasive developmental disorder) 587
 - assessment 591–3
 - biological factors 588–9
 - child focused interventions 594
 - clinical picture 586–8
 - co-morbidity 587
 - definition and classification 586
 - differential diagnosis 587
 - epidemiology 586
 - familial factors 588
 - fear in child and mother 588
 - history taking 591–2
 - ICD criteria 586
 - information from files 592
 - information from other agencies 593
 - interviews with parents and child 593
 - main features and symptoms 586–7
 - observation of child/caregiver interaction 592, 593
 - outcome for adopted children 596
 - outcome in non-clinical populations 595
 - outcome of family interventions 596

- outcome of insecure or disorganized attachment 595
- parent–child interaction interventions 595
- parent focused interventions 594
- pharmacological treatments 595
- providing a primary attachment figure in institutions 595
- relationship with disorganized attachment 587–8
- removal from parental care 595
- social factors 588
- treatment 593–5
- treatment within the family 593–5
- reading difficulties and dyslexia
 - aetiology 435–8
 - antisocial behaviour 444
 - assessment 434–5
 - clinical implications of epidemiology 426
 - clinical picture 426–8, 431
 - cognitive deficits 435–6
 - co-morbidity 434
 - definition and classification 417–20, 421, 422, 424
 - diagnostic instruments in the public domain 446
 - differential diagnosis 433
 - DSM-IV and ICD-10 criteria 417–20, 421, 422, 424
 - dyslexia developmental course 427–8, 431
 - dyslexia in adulthood 428, 431
 - dyslexia in early school years 427–8, 429
 - dyslexia in middle school years 428, 429–30
 - dyslexia in preschool stage 427, 428
 - dyslexia in secondary school and young adulthood 428, 430–1
 - educational attainments 443
 - educational management and treatment setting 439
 - effects of different languages 425
 - epidemiology 424–5
 - genetic influences 436
 - information for parents and children (websites) 446
 - interventions 439–41
 - outcome 442–4
 - persistence of reading problems 442–3
 - prevalence and incidence 424–5
 - process of learning to read and spell 426–7
 - psychosocial influences 437–8
 - psychosocial outcomes 443–4
 - range of specific learning difficulties 417
 - reading and the brain 437
 - sex ratios 425
 - treatment 438–41
 - treatment monitoring and evaluation 441
- receptive language disorder 389–90, 392, 394–5, 398–9, 400, 407–11
 - aetiology 409
 - assessment 400, 409
 - clinical implications of epidemiology 408
 - clinical management and treatment setting 410
 - clinical picture 394–5, 398–9, 400, 408–9
 - definition and classification 389–90, 392, 407–8
 - diagnostic instruments 398–9, 409
 - differential diagnosis and co-morbidity 409
 - epidemiology 408
 - IDC-10 and DSM-IV-TR criteria 389–90, 392, 407–8
 - improving language comprehension skills 410
 - information for patients and parents 410–11
 - main features and symptoms 394–5, 408–9
 - outcome 394–5, 411
 - pharmacotherapy 410
 - prevalence rates 408
 - prognostic factors 411
 - sex ratios 408
 - short- and long-term outcome 394–5, 411
 - treatment 410–11
 - treatment monitoring and evaluation 410
- Rett syndrome
 - and autism spectrum disorders 448, 462
 - and mental retardation 370–1, 373–4
- rubella
 - brain disorders due to 17, 18–19
 - embryopathy and autism spectrum disorders 462, 466
- Sanfillipo syndrome, and hyperkinetic disorders 498
- schizophrenia and schizophrenia-like disorders
 - aetiology 91
 - age-related incidence 84
 - and obsessive-compulsive disorders 193–4
 - and substance misuse/substance use disorders 59–62, 91, 99
 - antipsychotic drugs and dosages 93–5, 96
 - assessment 89–90, 91
 - brief psychotic episodes 83, 88
 - childhood and adolescent onset 79–80
 - clinical implications of epidemiology 85
 - clinical interview 89, 103–7

- schizophrenia (*cont.*)
- clinical management 91–2
 - clinical picture 85–7, 90, 91, 103–7
 - clozapine for treatment resistant schizophrenia 100–1
 - cognitive behavioural strategies 96–7
 - compliance therapy and concordance enhancing strategies 96–7
 - consents and assents 92
 - cultural and societal factors 85
 - definition and classification 80–1, 82, 84, 92
 - delusions and hallucinations 85–6, 88
 - diagnostic instruments 89, 103–7
 - differential diagnosis and co-morbidity 86–7, 89
 - disorganized symptoms 85–6
 - distinction from affective disorders 87
 - epidemiology 84–5
 - family assessment 89–91
 - follow-up and regular risk evaluation 97–8, 107–9
 - genetic component 91
 - hallucinations and delusions 85–6, 88
 - hallucinations due to non-psychotic conditions 88
 - hebephrenic or disorganized subtype 85–6
 - ICD-10 and DSM-IV diagnostic criteria 80–1, 82, 83, 84, 92
 - induced delusional or shared psychotic disorders 83, 88
 - information for patients and families 98
 - lack of treatment concordance 99–101
 - liaison with school, college or place of employment 97
 - main features and symptoms 85–6
 - main features of schizophrenia 80–1, 82, 83
 - medical condition-induced psychotic symptoms 88
 - mood disorders with psychotic features 84
 - negative symptoms 85–6
 - neurodevelopmental and neurodegenerative causes 91
 - ongoing psychiatric care 101
 - outcome 101–2
 - pharmacotherapy 93–5, 96
 - physical assessment 89–90, 91
 - positive symptoms 85–6
 - prevalence and incidence rates 84
 - problematic issues 99–101
 - prodromal period 85–6, 88–9
 - prognostic factors 102
 - psychological interventions 96–7
 - psychometric assessment 89–91
 - psychotic disorders due to general medical conditions 84
 - psychotic disorders induced by substance use 84
 - reducing high levels of expressed emotion 96–7
 - schizoaffective disorders 84, 99
 - schizophreniform disorder 80–1, 82, 83, 464–5
 - schizophreniform psychosis and infectious disorders of the brain 18–19
 - sex ratios and ethnicity 85
 - short and long term outcomes 101–2
 - social care needs assessment 97
 - substance-induced psychotic disorders 87–8
 - suicide risk 99
 - support and information for patient and family 96–7
 - transition to adult services 101
 - treatment 91–3, 94, 95, 98, 101, 107–9
 - treatment monitoring and evaluation 97–8, 107–9
 - treatment resistance 99–101
 - treatment setting 92–3
 - voluntary sector support 97
 - selective mutism *see* elective mutism
 - semantic pragmatic disorder, and autism spectrum disorders 464–5
 - separation anxiety disorder (SAD) 145–7, 150, 151–2
 - aetiology of anxiety disorders 170–1
 - assessment 150, 151–2, 181–4
 - benzodiazepines 174
 - clinical implications of epidemiology 148
 - clinical picture 148–50, 151–2
 - cognitive-behaviour therapy (CBT) 151–2, 171–2, 173
 - combined psychosocial and pharmacological treatments 176–7
 - combining treatments in a multidisciplinary approach 176–9
 - conditioning effects of life events 170–1
 - definition and classification 145–7
 - differential diagnosis and co-morbidity 149
 - disease management model for anxiety disorders 176
 - DSM-IV and ICD-10 classification 145–7
 - epidemiology 147–8
 - genetic predisposition for anxiety 170–1
 - main features and symptoms 148–9

- multidisciplinary approach 176–9
- outcome for anxiety disorders 179–80
- perceptual distortions 148–9
- pharmacological interventions 173–6
- prevalence and incidence rates 147–8
- psychosocial approach to treatment 176
- psychosocial interventions 151–2, 171–2, 173
- school refusal 148–9, 150
- serotonin reuptake inhibitors (SSRIs) 175–6
- sex ratios and ethnicity 148
- sleep difficulties 148–9
- stages-of-treatment model 177–9
- tantrums 148–9
- treatment of anxiety disorders 151–2, 171–2, 173, 178
- tricyclic antidepressants 174–5
- sex chromosome aneuploidies, and autism
 - spectrum disorders 462, 466
- sex reassignment *see* gender identity disorder
- sexual abuse *see* physical and sexual abuse
- sleep disorders *see also* excessive daytime sleepiness (EDS); parasomnias; sleeplessness
 - actigraphy 311
 - alertness level variations during 24 hours 305–6
 - and brain injury 5–6
 - and epilepsy 29–30, 31
 - assessment 309–10, 312
 - classification of sleep disorders 307–8, 309
 - effects of shift work 307
 - forms of sleep (REM and NREM) 305–6
 - ICSD-R classification system 307–8, 309
 - links with psychiatry 304–5
 - Non-rapid Eye Movement (NREM) sleep 305–6
 - normal sleep in childhood and adolescence 305–6
 - polysomnography (PSG) 311
 - Rapid Eye Movement (REM) sleep 305–6
 - sleep diary 310–11
 - sleep disorders medicine 304–5
 - sleep history and general review 309–10
 - sleep problems and underlying disorders 307–9
 - sleep quality 307
 - sleep requirements at various ages 305–6
 - Slow Wave sleep (SWS) 305–6
 - timing of sleep 305–6
 - types of sleep disturbance 307
 - video recording 311
- sleepiness *see* excessive daytime sleepiness (EDS)
- sleeplessness 312–21, 322 *see also* sleep disorders
 - adolescents 316–17, 319
 - aetiology 319–20
 - assessment 317–19
 - classes of causes
 - clinical implications of epidemiology 313–14
 - clinical picture 314–19
 - co-sleeping of small children with parents 313
 - definition and classification 312–13
 - differential diagnosis and co-morbidity 317
 - drug treatment 320–2
 - DSPS (delayed sleep phase syndrome) 315–17
 - effects on child's development 313–14
 - effects on child's family 313–14
 - epidemiology 313–14
 - groups with high rates of sleep problems 313
 - infants and toddlers 314–15, 318
 - main features and symptoms 314–17
 - outcome 322
 - preschool and school age children 315–16, 318–19
 - prevalence and incidence rates 313
 - restless legs syndrome 315–16
 - scheme to identify causes 317–19
 - severity of 312–13
 - sex ratios and ethnicity 313
 - 'sleep hygiene' principles 320–1, 322
 - treatment 320–1, 322
- Smith–Magenis syndrome
 - and autism spectrum disorders 462
 - and mental retardation 370–1, 373
- social phobia (social anxiety disorder) 151–2, 162–4, 165, 166
 - aetiology of anxiety disorders 170–1
 - anxiety disorders in family members 166
 - assessment 151–2, 166
 - benzodiazepines 174
 - clinical implications of epidemiology 165
 - clinical picture 151–2, 165–6
 - cognitive-behaviour therapy (CBT) 151–2, 171–2, 173
 - combined psychosocial and pharmacological treatments 176–7
 - combining treatments in a multidisciplinary approach 176–9
 - conditioning effects of life events 170–1
 - cultural variation in children's social roles 163–5
 - definition and classification 162–3, 164, 165
 - differential diagnosis and co-morbidity 166
 - disease management model for anxiety disorders 176
 - DSM-IV and ICD-10 criteria 162–3, 164, 165

- social phobia (*cont.*)
 - epidemiology 163–5
 - genetic predisposition for anxiety 170–1
 - main features and symptoms 165–6
 - multidisciplinary approach 176–9
 - outcome for anxiety disorders 179–80
 - pharmacological interventions 173–6
 - prevalence and incidence rates 163
 - psychosocial approach to treatment 176
 - psychosocial interventions 151–2, 171–2, 173
 - serotonin reuptake inhibitors (SSRIs) 175–6
 - sex ratios and ethnicity 163–5
 - social skills deficits 165–6
 - stages-of-treatment model 177–9
 - treatment of anxiety disorders 151–2, 171–2, 173, 178
 - tricyclic antidepressants 174–5
- somatiform disorders
 - aetiology 255–8
 - assessment 255
 - assessment and planning of treatment 258
 - chronic fatigue syndrome (neurasthenia) 247, 251–2, 255–6, 260–1, 265–7
 - clinical implications of epidemiology 249–50
 - clinical management and treatment setting 258–9
 - clinical picture 250–5
 - cognitive-behavioural family interventions 260–1
 - conversion (dissociative) disorder 247, 250–1, 265–7, 268–9
 - definition and classification 247, 265–70
 - diagnostic instruments 254, 270, 271
 - differential psychiatric diagnosis 252–3
 - DSM-IV classification 247, 267–70
 - educational concerns and social factors 257–8
 - epidemiology 247–50
 - excess of medical investigations 252
 - family health factors 257
 - family work 260
 - functional impairment 251–2
 - glandular fever and chronic fatigue syndrome 255–6
 - headaches 250, 260–1
 - ICD-10 classification 247, 267–70
 - illness beliefs 256–7
 - indications of psychological factors 250
 - information to patients and parents 262–3
 - in-patient admission 262
 - loss of bodily sensations or movement 247, 250–1, 265–7, 268–9
 - main features and symptoms 246–7, 250–2
 - neurasthenia (chronic fatigue syndrome) 247, 251–2, 255–6, 260–1, 265–7
 - outcome 263
 - pain disorder 247, 265–7, 269–70
 - parental mental distress 257
 - patient support groups 262–3
 - personality factors 256
 - pharmacotherapy 261
 - physical problems as precipitants 255–6
 - precipitants and stress 255–6
 - prevalence rates in paediatric clinics 249
 - prevalence rates in the general population 247–8
 - prevention 263–4
 - problematic issues 263
 - pseudoseizures 251
 - psychiatric co-morbidity 253–4
 - psychological interventions 259–60
 - psychosocial stress and events as precipitants 255–6
 - referral to child psychiatrist 250–5
 - school-related stresses 260
 - sex and age ratios 249
 - somatization disorder 247, 265–8
 - stomach aches 250, 260–1
 - summary 264
 - treatment 258–63
 - treatment assessment and planning 258
 - treatment effectiveness 260–1
 - treatment monitoring and evaluation 262
- specific (isolated) phobias 151–2, 166–7, 168, 170
 - aetiology of anxiety disorders 170–1
 - animal phobias 166–8
 - assessment 151–2, 169–70
 - benzodiazepines 174
 - blood-injection-injury phobias 166–8
 - clinical implications of epidemiology 169
 - clinical picture 151–2, 169–70
 - cognitive-behaviour therapy (CBT) 151–2, 171–2, 173
 - combined psychosocial and pharmacological treatments 176–7
 - combining treatments in a multidisciplinary approach 176–9
 - conditioning effects of life events 170–1
 - definition and classification 166–7, 168
 - differential diagnosis and co-morbidity 169

- disease management model for anxiety disorders 176
- DSM-IV and ICD-10 criteria 166–7, 168
- epidemiology 168
- genetic predisposition for anxiety 170–1
- main features and symptoms 169
- multidisciplinary approach 176–9
- natural environment phobias 166–8
- outcome for anxiety disorders 179–80
- pharmacological interventions 173–6
- prevalence and incidence rates 168
- psychosocial approach to treatment 176
- psychosocial interventions 151–2, 171–2, 173
- serotonin reuptake inhibitors (SSRIs) 175–6
- sex ratios and ethnicity 168–9
- situational phobias 166–8
- stages-of-treatment model 177–9
- treatment of anxiety disorders 151–2, 171–2, 173, 178
- tricyclic antidepressants 174–5
- types of specific phobias 166–8
- specific developmental disorders of speech and language 388–90
 - acquired aphasia with epilepsy (Landau–Kleffner syndrome) 27–8, 40, 389–90, 400, 411–15
 - expressive language disorder 389–90, 392, 394–5, 398–9, 400, 402–7
 - ICD-10 criteria 388–90
 - receptive language disorder 389–90, 392, 394–5, 398–9, 400, 407–11
 - specific speech articulation disorder 390–2, 394–5, 398–9, 400, 402
- specific learning difficulties, and hyperkinetic disorders 499
- specific speech articulation disorder 390–2, 394–5, 398–9, 400, 402
 - aetiology 399
 - assessment 397–9, 400
 - children exposed to multiple languages 397–9, 402
 - clinical implications of epidemiology 393
 - clinical management and treatment setting 399–400
 - clinical picture 393–5, 398–9, 400
 - definition and classification 389–91, 392
 - diagnostic instruments 397, 398–9
 - differential diagnosis and co-morbidity 396–7
 - epidemiology 391–3
 - ICM-10 and DSM-IV-TR criteria 389–91, 392
 - information for patients and parents 401
 - interventions (phonological and traditional) 400–1
 - main features and symptoms 393–5, 396
 - outcome 402
 - pharmacotherapy 401
 - prevalence rates 391
 - problematic issues 402
 - prognostic factors 402
 - sex ratios 391
 - short- and long-term outcome 402
 - speech development 393–5, 396
 - treatment 399–402
 - treatment monitoring and evaluation 401
- speech and language disorders
 - acquired aphasia with epilepsy (Landau–Kleffner syndrome) 27–8, 40, 389–90, 400, 411–15
 - and autism spectrum disorders 466–7
 - expressive language disorder 389–90, 392, 394–5, 398–9, 400, 402–7
 - ICD-10 criteria for specific developmental disorders 388–90
 - receptive language disorder 389–90, 392, 394–5, 398–9, 400, 407–11
 - specific developmental disorders 388–90
 - specific speech articulation disorder 390–2, 394–5, 398–9, 400, 402
- subcultural deviance, and conduct disorders 532
- substance use disorders 54
 - abuse potential of psychotropic medications 71–2
 - accidents due to 58–9
 - aetiology 64–5, 67
 - Alcoholics Anonymous (AA) 67–9
 - assessment 62–4, 75–6, 77, 78
 - association with ADHD 59–60, 62
 - association with anxiety disorders 59–62
 - association with bulimia nervosa 59–62
 - association with conduct disorders 59–60, 62
 - association with depressive disorders 59–62
 - association with post-traumatic stress disorder 59–62
 - association with schizophrenia 59–62
 - association with suicide 59–62
 - behavioural changes 58–9
 - clinical implications of epidemiology 58
 - clinical management and treatment setting 67–9
 - clinical picture 60, 75–6, 77, 78

- substance use disorders (*cont.*)
 - co-existing disruptive behaviour disorders 59–60, 62
 - co-existing mood disorders 59–60, 62
 - cognitive changes 58–59
 - co-morbid psychiatric disorders 58–60, 62
 - definition and classification 54–6
 - development and maintenance of the disorders 64–5, 67
 - diagnostic instruments 62, 75–6
 - differential diagnosis and co-morbidity 59–60, 62
 - DSM IV diagnoses 54–6
 - epidemiology 56–8
 - experimentation with ‘gateway drugs’ 64–7
 - family interventions 69–70
 - HIV risk 58–9
 - ICD-10 diagnoses 54–6
 - main features and symptoms 58–9
 - medical consequences 58–9
 - medications to target cravings 71
 - mood changes 58–9
 - Narcotics Anonymous (NA) 67–9
 - negative effects of group treatment 68
 - outcome 72–3
 - peer-based self-support groups 67–9
 - prevalence and incidence rates 56–7
 - psychoeducational measures 71
 - psychological interventions 69–70
 - psychopharmacology 71–2
 - psychosocial and academic impairment 58–9
 - risk factors for 64–5, 67
 - sex ratios and ethnicity 57
 - stages of adolescent substance abuse 64–7
 - studies of adolescent treatment outcomes 72–3
 - substance abuse diagnoses 54–6
 - substance dependence diagnoses 54–6
 - treatment 67–72
 - treatment goals 67–9
 - treatment of co-morbid ADHD 71–2
 - treatment of co-morbid mood problems 71–2
 - treatment of co-morbid psychiatric conditions 71–2
 - unsafe sexual behaviour 58–9
 - use of psychotropic medications 71–2
- suicide risk
 - and bulimia nervosa 293
 - and depressive disorders 119–20, 121–2
 - and schizophrenia 99
 - and substance use disorders 59–62
- tic disorders 598
 - aetiology 609–13
 - and autism spectrum disorders 463, 478
 - and emotional disorders 606–7
 - and epilepsy 29–30, 31
 - and hyperkinetic disorder 498, 605, 606
 - and infectious disorders of the brain 17, 18–20, 22
 - and learning problems 607
 - and medical illnesses 603
 - and obsessive-compulsive disorder (OCD) 605–6
 - and psychiatric disorders 603–6
 - and sleep disorders 607
 - assessment 599, 607–9, 622
 - behavioural therapy 618–20
 - biological factors 610–11
 - clinical implications of epidemiology 600–2
 - clinical management and treatment setting 613–14, 615
 - clinical picture 602–4, 605, 606, 608, 609
 - cues which can prompt or decrease tics 603
 - definition and classification 598–9, 600, 601
 - differential diagnoses and co-morbidity 603–4, 605, 606, 607
 - duration and severity of tic bouts 602–3
 - epidemiology 599–602
 - epigenetic factors 610
 - genetic factors 610
 - ICD-10 and DSM-IV criteria 598–9, 600, 601
 - main features and symptoms 598–9, 600, 601, 602–3
 - motor and vocal tics 602–3
 - neurophysiological mechanisms 611, 612
 - outcome 620–1
 - pharmacotherapy 614–16, 618
 - post-infectious autoimmune mechanisms 610–11
 - post-monitory urges 602
 - premonitory sensory motor sensations 602
 - prevalence and incidence rates 599–600
 - psychoeducational measures and rehabilitation 620
 - psychological interventions 618–20
 - psychosocial risk factors 611–13
 - sex ratio and ethnicity 600
 - treatment 613–16, 619, 620
- Tourette syndrome
 - aetiology 609–13
 - and autism spectrum disorders 463

- and emotional disorders 606–7
- and epilepsy 29–30, 31
- and hyperkinetic disorders 498, 605, 606
- and infectious disorders of the brain 18–20
- and learning problems 607
- and medical illnesses 603
- and obsessive-compulsive disorder (OCD)
 - 193–4, 605–6
- and psychiatric disorders 603–6
- and sleep disorders 607
- assessment 599, 607–9, 622
- behavioural therapy 618–20
- biological factors 610–11
- clinical implications of epidemiology 600–2
- clinical management and treatment setting
 - 613–14, 615
- clinical picture 602–4, 605, 606, 608, 609
- cues which can prompt or decrease tics 603
- definition and classification 598–9, 600, 601
- differential diagnoses and co-morbidity 603–4,
 - 605, 606, 607
- duration and severity of tic bouts 602–3
- epigenetic factors 610
- genetic factors 610
- ICD-10 and DSM-IV criteria 598–9, 600, 601
- main features and symptoms 602–3
- motor and vocal tics 602–3
- neurophysiological mechanisms 611, 612
- outcome 620–1
- pharmacotherapy 614–16, 618
- post-infectious autoimmune mechanisms
 - 610–11
- post-monitory urges 602
- premonitory sensory motor sensations 602
- prevalence and incidence rates 599–600
- psychoeducational measures and rehabilitation
 - 620
- psychological interventions 618–20
- psychosocial risk factors 611–13
- sex ratio and ethnicity 600
- treatment 613–16, 619, 620
- tuberous sclerosis
 - and autism spectrum disorders 462, 466
 - and hyperkinetic disorders 498
 - and mental retardation 370–1
- Williams syndrome, and hyperkinetic disorders
 - 498